GlassScriptPhysician profile
Marc I Lindner
NPI 1891138236
$8,253.88
in general payments reported to CMS, 2019-2025
37 companies · $1,790 in 2025
The $1,790 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $567 · 2021: $740 · 2022: $1,995 · 2023: $1,225 · 2024: $1,394 · 2025: $1,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,150 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,149.82 |
| Education | $258.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,469.01 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,182.39 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $680.70 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| United Therapeutics Corporation | $584.03 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $504.57 | 2021-2025 | |
| Astellas Pharma US INC | $499.82 | 2021-2025 | Cresemba |
| La Jolla Pharmaceutical Company | $376.01 | 2021-2023 | Giapreza |
| Insmed, INC. | $344.44 | 2023-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $288.57 | 2019-2025 | Fasenra, Tezspire |
| Merck Sharp & Dohme LLC | $227.74 | 2020-2025 | Winrevair, Keytruda |
| Mylan Specialty L.P. | $221.17 | 2022-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $209.85 | 2020-2025 | Livtencity, Aralast, Glassia |
| Ethicon INC. | $168.94 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $158.51 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $155.62 | 2022-2024 | Dupixent |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $148.03 | 2022-2023 | Ultomiris |
| Pulmonx Corporation | $129.19 | 2020-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Csl Behring | $125.00 | 2020 | |
| Shionogi INC | $124.70 | 2023 | Fetroja |
| Viatris Specialty LLC | $95.20 | 2025 | Yupelri |
| Eurofins Viracor, LLC | $86.69 | 2024 | |
| Janssen Pharmaceuticals, INC | $76.56 | 2020-2023 | Xarelto |
| Mallinckrodt Hospital Products INC. | $68.11 | 2023-2024 | Acthar |
| Pfizer INC. | $48.17 | 2020-2024 | |
| Vifor Pharma, INC. | $34.00 | 2024 | Zemaira |
| Novo Nordisk INC | $33.48 | 2024 | Wegovy |
| Kamada LTD. | $32.93 | 2025 | |
| 3b Medical, INC. | $30.81 | 2024 | Luna |
| Akcea Therapeutics, INC. | $26.71 | 2020 | |
| Electromed, INC. | $17.68 | 2025 | Smartvest |
| Invivyd INC | $17.67 | 2025 | Pemgarda |
| Pharming Healthcare, INC. | $16.00 | 2023 | Ruconest |
| Harmony Biosciences LLC | $15.00 | 2022 | |
| Shire North American Group INC | $14.68 | 2019 | |
| Amgen INC. | $14.48 | 2019 | |
| Gilead Sciences, INC. | $14.03 | 2025 | Veklury |
| Ani Pharmaceuticals, INC. | $13.39 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Lindner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.